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Abstract
Background:  Mefloquine and artesunate combination therapy is the recommended first-line treatment for
uncomplicated malaria throughout much of south-east Asia. Concerns have been raised about the potential central
nervous system (CNS) effects of both drug components and there are no detailed reports in very young children.
Methods: Children, aged between three months and five years, with acute uncomplicated Plasmodium falciparum malaria
were randomized to either 7 days of artesunate monotherapy or the same schedule of artesunate plus mefloquine on
day 7 and 8. Neurological testing targeting coordination and behaviour was carried out at day 0, 7, 9, 10, 14 and 28. Non-
febrile healthy control children from the same population were tested on days 0, 7, 14 and 28.
Results: From December 1994 to July 1997, 91 children with uncomplicated P. falciparum, 45 treated with artesunate
monotherapy, 46 treated with mefloquine and artesunate combination therapy and 36 non-febrile controls, underwent
neurological testing. Malaria and fever had a significant negative impact on testing performance. By contrast, the anti-
malarial treatments were not associated with worsening performances in the various components of the test. Artesunate
and mefloquine do not appear to have a significant influence on coordination and behaviour. Children treated with
mefloquine were significantly less likely to suffer recurrent malaria infection during follow-up compared to those treated
with artesunate alone (P = 0.033).
Conclusion: In keeping with the results of randomized controlled trials in adults, mefloquine was not associated with a
decrease in specific items of neurological performance. Likewise, children treated with artesunate did not perform
significantly differently to control children. This study does not exclude subtle or rare treatment CNS effects of
artesunate or mefloquine. Treatment of acute uncomplicated malaria results in a significant improvement on items of
neurological performance.
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Background
In 2006, the WHO recommended the use of artemisinin
combination therapy (ACT) as the first-line treatment of
uncomplicated falciparum malaria[1]. Mefloquine in
combination with artesunate has been the first-line treat-
ment on the western border of Thailand for 15 years and
is recommended in much of south-east Asia [2], where
strains of multiple-drug-resistant parasites are common
[3]. The safety and efficacy of mefloquine-artesunate com-
bination treatment for uncomplicated falciparum malaria
is well-established [4-7].
Since the study reported here was undertaken (in 1994),
the CNS adverse effects and particularly the neuropsychi-
atric effects of mefloquine have been the focus of publica-
tions including several reviews [8-11]. Published data on
the neuropsychiatric effects of mefloquine come from
more than 25,000 patients (20 trials) with dizziness and
anxiety reported most commonly in adults [11,12], as
well as vomiting, especially in young children [9]. These
effects are dose-related [8]. There were concerns that the
CNS adverse effects reported by the manufacturer such as
dizziness, vertigo and headache could affect those operat-
ing machinery and this was studied in adults. There was
no functional compromise in American soldiers who took
weekly mefloquine (preceded by the loading dose) as
prophylaxis, despite more reporting sleep disturbances,
increased dream activity and depression [13]. In a double-
blind, placebo-controlled, cross-over study of 23 Swiss
trainee pilots, mefloquine was given as a loading dose,
followed by weekly administration for three weeks [14].
There were no significant differences in flying perform-
ance, psychomotor functions and postural sway between
the two arms, although a non-significant reduction in
sleep quality was reported by the mefloquine recipients.
Similar findings were reported in another placebo-con-
trolled trial of mefloquine prophylaxis and the effect of
alcohol when driving a car [15]. In 10 volunteers, meflo-
quine had no effect on audiometry and vestibular func-
tions [16]. A study of 73 volunteer Dutch marines,
stationed in Cambodia, who used mefloquine for proph-
ylaxis also reported a low risk of adverse events, including
coordination problems, during the three-month follow
up [17]. These data suggest that, although mefloquine is
often associated with CNS effects, it does not interfere
with coordination tasks requiring higher cognitive func-
tion in adults. Data on the neuropsychiatric effects of
mefloquine in young children is limited to a single study
with mefloquine monotherapy, which found no evidence
for such an effect in children less than five years of age,
when treated for falciparum  or  vivax  malaria[18]. As
described by the authors, they lacked a sensitive and
objective tool for the assessment of neurological status in
this age group and any neurological disturbance less cata-
strophic than convulsion, major behavioural change, or
encephalopathy could not be excluded.
The artemisinin derivatives, characterized by Chinese sci-
entists in the early 1970s [19-21], have been associated
with CNS toxicity in animals. In one study, dogs treated
with high doses of intramuscular artemether or arteether
developed gait disturbances, loss of spinal and pain
response reflexes, and prominent loss of brain stem and
eye reflexes. This lead to cardiorespiratory depression and
death in five out of six animals, as a result of selective
damage to the brain stem, particularly to the reticular for-
mation, the vestibular system and nuclei related to the
auditory system [22]. Rats and Rhesus monkey given
arteether or artemether showed a similar selective pattern
of brain stem pathology [23,24]. These neurotoxic effects
have not been found in human trials that have examined
coordination (heel-toe ataxia), fine finger dexterity, hear-
ing, nystagmus and balance (Romberg's test) in patients
(>5 years) treated with artemether or artesunate as mono-
therapy or with mefloquine [25]. Selected testing for audi-
ometry and auditory evoked potentials in patients treated
with artemisinin derivatives [26,27] or with the combina-
tion of artesunate and mefloquine [28] also failed to find
any detrimental artemisinin effect. In addition, brain-
stems of adults who died after treatment with high dose
artemether or quinine for severe falciparum malaria
showed no evidence of selective neuronal damage[29].
This aim of this study was to examine, in a resource-poor
setting, the potential neurotoxicity of treatment doses of
artesunate and mefloquine given to young children (< 5
years age) with acute falciparum malaria. No single stand-
ardized test that focused on ataxia, irritability, behav-
ioural and tone change in children of this age, and could
be easily applied in remote clinics by local health workers,
existed for this problem. Hence items of interest that spe-
cifically examined for coordination and behaviour were
selected from previously standardized tests. Age-matched
healthy children from the same community were included
as controls to elucidate practice effects and as a compara-
tor group for normal neurological test results in this age
group.
Methods
This study was approved by the ethical committee of the
Faculty of Tropical Medicine, Mahidol University, Bang-
kok and the Karen Ethics Committee, Mae Sot, Thailand.
Participants
Young children from three months to five years of age,
attending the clinics of Shoklo Malaria Research Unit in
Maela Refugee camp on the western border of Thailand
with Burma, were considered for enrolment if they pre-
sented with symptomatic, microscopically confirmed
Plasmodium falciparum malaria. They were excluded if they
had signs of severe or complicated malaria[30], a concom-
itant severe disease which required hospitalization, or any
underlying neuro-developmental condition, includingMalaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
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epilepsy. Controls were not randomly selected. They were
the relatives of children in the study who were selected
because their parents volunteered them after invitation,
they had a negative malaria smear, and were free from
medications and fever for at least 48 hours, and had a nor-
mal body temperature prior to neurological testing.
Protocol
If consent was forthcoming a full medical history and clin-
ical examination was carried out. This included assessing
the duration of symptoms before presentation and any
drugs taken prior to arrival at the clinic. Daily malaria
smears were made until the patient was malaria smear
negative. Temperature was measured daily until the
patient was afebrile. Patients under treatment had daily
clinical examination, drug administration, and adverse
events documented on a case record form.
Anti-malarial drug treatments
Participants with acute uncomplicated falciparum malaria
received either artesunate alone (AS7), or artesunate in
combination with mefloquine (MAS7). The total dose of
artesunate was 12 mg/kg and the total dose of mefloquine
was 25 mg/kg. Treatment regimes were as follows:
AS7: Artesunate 2 mg/kg for days 0 to 4, then 1 mg/kg for
days 5 and 6.
MAS7: Artesunate 2 mg/kg for days 0 to 4, then 1 mg/kg
on days 5 and 6; Mefloquine 15 mg/kg day 7 and 10 mg/
kg day 8.
The protocol for drug administration was to calculate the
target dose per body weight, crush the tablets in water and
give with sugar, biscuits or milk. This was done by inject-
ing the suspension into the mouth with a 5-ml syringe fol-
lowed by milk and food if tolerated. If vomiting occurred
within the first 30 minutes, the entire dose was repeated.
If vomiting occurred between 30 minutes and 1 hour
later, half the initial dose was repeated. Repeat dosing was
given via nasogastric tube.
Reappearance of P. falciparum was treated with 7 days of
artesunate, and mefloquine if it had not been prescribed
in the previous 2 months. Treatment of Plasmodium vivax
infections was with a standard chloroquine regimen (25
mg base/kg over 3 days).
Clinical outcome
Clinical assessment was performed daily from day 0 to
day 5, then on days 7, 9, 10, then weekly until week 9.
Only the results up to day 28 are reported here. Follow-up
included basic clinical examination and weekly malaria
smear and haematocrit from day 0. In addition, on each
follow-up day, the parents or guardians of the participant
completed a questionnaire regarding occurrence of symp-
toms and side-effects.
Neurological outcome
Children with malaria were tested on days 0, 7, 9, 10, 14
and 28. Children completed the neurological assessment
before treatment on day 0, and on all other days were
treated then assessed. Control children were invited for
neurological examination on days 0, 7, 14 and 28. Testing
until day 28 was considered necessary due to the pharma-
cokinetic properties of mefloquine[31]. Mefloquine was
administered on days 7 and 8 so both treatment groups
had repeat neurological testing on days 9 and 10.
Neurological items predominantly assessing hand coordi-
nation (box, cube, ring, coin, and a timed item to place 6
and 12 coins into a slot in a coin box as fast as possible)
were adapted from the Griffiths Developmental Scales
[32] and the Movement ABC [33]; those assessing tone
and behaviour from the Hammersmith Infant Neurologi-
cal Examination [34]and the Bayley Scales of Infant
Development[35]. The complete testing procedure, appli-
cability and scoring in this population have been
described previously [36]. These tests were chosen
because they focused on coordination and concentration
which were the CNS adverse affects of mefloquine and
artesunate that were of greatest concern at the time. While
an adult can be asked about dizziness young children can-
not but it may be observed in items testing coordination
by for example ataxic movements.
Randomization
Children were randomized to one of two treatment
groups using a list of random numbers that were allocated
in a 1:1 ratio in blocks of 10. The randomization list was
generated by an independent statistician who was not
involved in conducting the study. The treatment alloca-
tion was concealed in envelopes labeled with the study
code by another person not involved in conducting the
study. The study envelopes were sorted by code and kept
at the field sites. Inclusion was sequential. Patients who
met the inclusion criteria were assigned the next available
code. The envelope was then opened and the patient
treated according to the allocation.
Blinding
The testing room was separate to the medical outpatient
department. Testers were kept blind to the treatment
group of the patients with malaria. Testers knew only
when patients belonged to the control group.
Laboratory procedure
Blood smears (thin and thick films) were prepared using
Giemsa staining and were read for 200 fields before being
declared negative. Uncomplicated falciparum malaria wasMalaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
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defined as slide-confirmed P. falciparum, with an asexual
parasitaemia (between 6/500 white blood cells and 40/
1,000 red blood cells, equivalent to 96 - 150,000 para-
sites/uL), in the absence of signs of severe malaria. Hyper-
parasitaemia was defined by a parasitaemia of ≥ 40/1000
RBC.
Haematocrit capillary tube samples were taken by finger
prick and centrifuged at 1,500 rev/min for three minutes
using a standard Hawksley™ haemotocrit reader. Anaemia
was defined as a haematocrit of less than 30%, and severe
anaemia by a haematocrit <20%.
Sample size calculation
The combination of mefloquine and artesunate was
expected to cause a 3 fold increase in worse outcomes
based on the increase in severe dizziness found in chil-
dren treated with high dose mefloquine in this area [37].
A sample size of 42 children in each group allowed a 3
fold higher incidence of worse outcomes (15 to 45%), to
be detected with 95% confidence and 80% power. A 15%
drop out was expected and 6 was added i.e 49 in each
group.
Statistical methods
Only children who completed a full course of treatment
according to the protocol and who had at least two days
of neurological testing, which included a test on day 0
(baseline), were included. Rather than use the overall
scores for the items of hand co-ordination, behaviour and
tone, some of which were age dependent, results of testing
on a specified day were compared to a prior day e.g. day 7
compared to day 0. Children could refuse to participate in
tests although they were all of an age where they could
potentially score on the test item. Hence a child might
refuse one week and get a top score the next week or vice
versa. Therefore for each item examined we chose to
assign the score as performed worse (score = 1), per-
formed the same (score = 2) or improved performance
(score = 3) in comparison to the previous score. Behaviour
was scored in the same way and tone was scored as tone
decreased (score = 1), tone stayed the same (score = 2) or
tone increased (score = 3). Neurological test results could
no longer be used once children were diagnosed with
recurrent malaria of any species. Differences in propor-
tions were compared using the Chi-squared test or Fisher's
exact test when appropriate. Normally distributed data
was compared using the mean and Student's T test. Data
that was not normally distributed was summarized by the
median and compared using the Mann Whitney U test
when independent or with Wilcoxon Signed Ranks Test
when paired at specified days. Statistical programmes
used were SPSS for Windows, version 11.0 (SPSS), and Epi
Info, version 3.4.0 (Centres for Disease Control and Pre-
vention).
Results
Study participants
Ninety-eight patients between the ages of three months
and five years with uncomplicated falciparum malaria
were randomized between 5th December 1994 and 29th
July 1997. Six patients did not have any paired neurolog-
ical data and one patient was treated before testing on day
0 and all these children were excluded from analysis. Of
the remaining 91 children, 45 were treated with artesu-
nate alone and 46 were treated with mefloquine and
artesunate. There were 36 control children, with a mean
age of 2.2 ± 1.2 [0.3-4.7] years, of whom 61.1% (22/36)
were male which was not significantly different from the
children with malaria (P = 0.871, P = 0.574, respectively).
In children with malaria, there were no significant differ-
ences between treatment groups on admission character-
istics (Table 1) or symptoms on admission (Table 2). After
starting treatment fever and other symptoms decreased,
and there was no significant difference in the proportion
of children who developed new symptoms (data not
shown). There was no difference in fever clearance time
between the groups. Participants who became smear-pos-
itive for either P. falciparum or P. vivax during follow-up
were retreated. Significantly more participants in the AS7
group become positive for malaria by day 28 than in the
MAS7 group: 21.7% (10/46) vs 4.4% (2/45), P = 0.033. In
the AS7 group one child had a mixed infection (P. falci-
parum and P. vivax) identified by day 14; the remaining
nine all had P. vivax, one of whom was diagnosed by day
14, and the rest were diagnosed by day 28. In the MAS7
group two children had P. falciparum identified at day 28.
Valid test scores
Many children refused testing on one or more items. The
proportion of valid test scores was consistently lower in
the malarial children than control children from day 0 to
day 28 (Figure 1). The differences between malaria and
control children were significant for box, cube, ring and
coin items on day 0 (P < 0.001 for all) and on day 7 (P =
0.037, P = 0.019, P = 0.032, P < 0.001, respectively), day
14 cube (P = 0.037) and coin (P = 0.001) and on day 28
only coin (P = 0.012). As the days post-treatment
increased there was a tendency in the malaria group
towards increasing proportions of valid test scores how-
ever it never reached the same high proportion as the con-
trol children. By day 28, only the coin task showed
significantly fewer valid test scores in the malaria group
compared to the control group (Figure 1). There were no
significant differences between the AS and MAS7 treat-
ment groups in the proportion of valid test scores (data
not shown) at each day of follow-up, on any neurological
item. Tone and behaviour test scores were nearly always
valid (Figure 1) regardless of the day of testing or group.Malaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
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On day 0 children with fever were less likely to have valid
test scores than non-febrile children for most items: box
62.7% (32/51) vs 82.9 (63/76), P = 0.013; cube 62.7%
(32/51) vs 86.8% (66/76), P = 0.002; and ring 64.7% (33/
51) vs 85.5% (65/76), P = 0.009. The proportion of febrile
children who were timed while putting 6 or12 coins
through a slot in a box (coin 6 and 12) was less than for
non-febrile children but the difference was not significant.
The median tone score in children with fever compared to
those without fever was significantly higher 11 [8-15]vs 11
[6-15], P = 0.020. The median behaviour score in children
with fever compared to those without fever was signifi-
cantly lower: 11 [6-15]vs 14 [6-15], P < 0.001. Tone was
negatively and significantly correlated with behaviour (P
= 0.007). Vomiting was also associated with a significant
increase in tone and decrease in behaviour scores com-
pared to those who did not vomit: 12 [8-15]vs 11 [6-15],
P = 0.013; 10 [6-15]vs 13 [6-15], P = 0.042, respectively.
Analysis of performance on day 7 and 28 compared to day 
0
Up to day 7, both malaria treatment groups received iden-
tical treatment with artesunate alone. There were no sig-
nificant differences in the proportion of hand co-
ordination, behaviour or tone scores that were worse,
compared to the same or improved, in the AS7 vs MAS7
groups for any item (Table 3). There were also no differ-
ences between malaria and controls on items of hand co-
ordination on the day 7 - day 0 comparison or on the day
28 - day 0 comparison, except for the ring task, which was
significantly worse in the controls. Behaviour improved
significantly more in the malaria treated children com-
pared to controls at both day 7 to day 0 and day 28 to day
0, with most of the improvement apparent by day 7. Con-
comitant to the fever clearance, tone decreased signifi-
cantly in malaria treated children at both the day 7 to day
0 and day 28 to day 0 comparisons (Table 3).
Table 1: Clinical characteristics on admission in the AS7 and MAS7 groups
Characteristic AS7 n = 45 MAS7 n = 46 P
Age, yrs, mean 2.3 ± 1.3 [0.4-5.0] 2.3 ± 1.3 [0.3-4.7] 0.940
Male, % 57.8 (26/45) 50.0 (23/46) 0.530
Weight, kg, mean 10 ± 3 [5-15] 10 ± 3 [5-17] 0.893
Height, cm, mean 80 ± 11 [61-102] 81 ± 10 [56-106] 0.891
PR, bpm, mean 130 ± 15 [100-160] 132 ± 14 [110-160] 0.645
Temperature, °C, mean 37.8 ± 1.0 [36-40.2] 37.9 ± 1.0 [36-40.0] 0.483
Proportion febrile, % 55.6 (25/45) 56.5 (26/46) 1.000
Palpable spleen, % 45.5 (20/44) 38.6 (17/44) 0.666
Palpable liver, % 52.3 (23/44) 47.7 (21/44) 0.831
Early vomiting day0, % 17.8 (8/45) 28.3 (13/46) 0.321
Haematocrit, % 30.3 ± 5.2 [16.7-39.5] 29.2 ± 5.5 [15.2-39.8] 0.329
Geometric mean parasitaemia/uL 3,981
[145-109,648]
3,090
[16-97,724]
0.575
History fever, days, median 2 [1-10] 2 [0-10] 0.925
Data % (n) unless otherwise stated;
Proportions compared with Chi-square test (or Fisher' exact), means with Student's t-test and medians with Mann Whitney U test.
Table 2: Symptoms on admission in the AS7 and MAS7 groups
Symptoms AS7 n = 45 MAS7 n = 46 P
Feels ill 97.8 (45/45) 97.8 (44/46) 1.000
Weakness 68.2 (30/44) 65.2 (30/46) 0.825
Stopped walking, sitting or crawling 42.2 (19/45) 34.8 (16/46) 0.522
Talk/babbles less 40.0 (18/45) 43.5 (20/46) 0.832
Feeding less 70.5 (31/44) 68.9 (31/45) 1.000
Refuse food 60.5 (26/43) 50.0 (22/44) 0.391
Sleeping badly 57.8 (26/45) 45.7 (21/46) 0.297
Crying more than normal 71.71 (32/45) 71.7 (33/46) 1.000
Playing less than normal 86.7 (39/45) 84.8 (39/46) 1.000
Eye contact reduced 13.6 (6/44) 21.7 (10/46) 0.411
Seek mum/guardian 48.9 (22/456) 39.1 (18/46) 0.402
Sad/depressed 75.6 (34/456) 76.1 (35/46) 1.000
Less responsive to mum 48.9 (22/45) 54.3 (24/46) 0.677
Strange behaviour 4.3 (2/45) 4.3 (2/46) 1.000
Smiling less 84.4 (38/45) 82.6 (38/46) 1.000Malaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
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Proportion of neurological items with a valid test score in young children, malaria and controls, at each day of follow-up, Day 0  (white square), Day 7 (light grey square), Day 14 (dark grey square) and day 28 (black square) Figure 1
Proportion of neurological items with a valid test score in young children, malaria and controls, at each day of 
follow-up, Day 0 (white square), Day 7 (light grey square), Day 14 (dark grey square) and day 28 (black square).
Table 3: Proportion of children with worse performance on day 7 and day 28 compared to day 0, after treatment with AS7 or MAS7 
for P. falciparum, and in the non febrile controls.
Day 7 - Day 0
Neurological Test
Component
Result compared to previous test AS7
N = 39
MAS7
N = 39
Controls non febrile
N = 35
P*
2 × 2a
2 × 2b
Box Worse 11.6 (5) 16.3 (7) 11.4 (4) 0.757
0.455
Cube Worse 14.0 (6) 16.3 (7) 31.4 (11) 1.000
0.186
Ring Worse 11.6 (5) 11.6 (5) 11.4 (4) 1.000
0.285
Coin Worse 4.7 (2) 2.3 (1) 2.9 (1) 1.000
0.178
Behaviour Worse 11.6 (5) 14.0 (6) 31.4 (11) 1.000
< 0.001
Tone Decreased 41.9 (18) 40.5 (17) 8.8 (3) 1.000
0.026
Day 28 - Day 0
Box Worse 5.1 (2) 7.7 (3) 9.7 (3) 1.000
0.686
Cube Worse 15.4 (6) 20.8 (8) 16.1 (5) 0.769
1.000
Ring Worse 5.1 (2) 7.7 (3) 25.8 (8) 1.000
0.009
Coin Worse 5.1 (2) 5.1 (2) 9.7 (3) 1.000
0.403
Behaviour Worse 15.4 (6) 10.3 (4) 45.2 (14) 0.737
0.001
Tone Decreased 51.3 (20) 44.7 (17) 19.4 (6) 0.650
0.009
*P value comparison of proportions a of 2 × 2 for AS7 vs MAS7, b 2 × 2 tables for malaria treatment pooled vs controlsMalaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
Page 7 of 11
(page number not for citation purposes)
Analysis of performance on day 9, 10 and 14 compared to 
day 7
The proportion of children with worse scores for items of
hand co-ordination on days 9, 10 and 14 compared to day
7 items, was not significantly different between meflo-
quine-and artesunate-treated children and those treated
with artesunate alone (Table 4). Likewise behaviour
scores were not significantly worse and tone scores did not
decrease significantly once mefloquine treatment was
given to the children (Table 4).
Comparison of timed coin box item at each day of 
examination
For this item children were required to put 6 or 12 coins
into the coin box as fast as they could. Approximately half
the children were unable to score on this item (Figure 1).
Improvement on this item was reflected by a reduced time
(seconds) to complete the task. The median time for each
day of testing was summarized and paired data was com-
pared for the specified days (Table 5). The mean age of
children who managed to score on this item was signifi-
cantly higher than those who did not complete this task:
6 coins; 3.4 ± 0.9 vs 1.7 ± 1.0 yrs and 12 coins; 3.4 ± 0.9 vs
1.8 ± 1.1 yrs, P < 0.001 for both. Nevertheless there was
no trend for significantly worse times at day 7 compared
to day 0 when an effect of artesunate may be noticed, nor
at day 9, 10 and 14 compared to day 7, when an effect of
mefloquine may be noticed. Although there are some sig-
nificantly faster times in the artesunate-mefloquine group
compared to artesunate alone group on day 7 and 9 and
day 7 and 10, a practice effect cannot be ruled out.
Discussion
This study represents the first attempt to focus specifically
on the occurrence of CNS effects in young children fol-
lowing a seven-day treatment with either artesunate mon-
otherapy or artesunate-mefloquine combination therapy
for acute uncomplicated falciparum malaria. Performance
on items testing co-ordination, behaviour and tone was
not significantly worsened by either treatment. The com-
parison of proportions of worse scores from day 28 to day
0 suggests there are no long-lasting effects of malaria
treated either with artesunate monotherapy or meflo-
quine-artesunate combination therapy.
Although the numbers of children able to perform the
timed test of 6 and 12 coins into the slot in the coin box
were limited, the data is useful as it clearly demonstrates
no severe nor frequent adverse effect of artesunate or
mefloquine on a test requiring concentration, co-ordina-
Table 4: Proportion of children with worse performance on day 9, 10 and 14 compared to day 7, in children with P. falciparum treated 
with AS7 or MAS7.
Day 9 - Day 7
Neurological Test Component Result compared to previous test AS7 N = 39 MAS7 N = 39 P*
Box Worse 17.9 (7) 20.5 (8) 1.000
Cube Worse 15.4 (6) 28.2 (11) 0.272
Ring Worse 12.8 (5) 20.5 (8) 0.545
Coin Worse 12.8 (5) 12.8 (5) 1.000
Behaviour Worse 33.3 (13) 30.8 (12) 1.000
Tone Decreased 46.2 (18) 53.8 (21^) 0.651
Day 10 - Day 7
AS7 N = 39 MAS7 N = 39 P*
Box Worse 12.8 (5) 15.4 (6) 1.000
Cube Worse 23.1 (9) 33.3 (13) 0.457
Ring Worse 5.1 (2) 20.5 (8) 0.087
Coin Worse 7.7 (3) 12.8 (5) 0.711
Behaviour Worse 25.6 (10) 30.8 (12) 0.802
Tone Decreased 38.5 (15) 50 (19^) 0.363
Day 14 - Day 7
AS7 N = 38 MAS7 N = 38 P*
Box Worse 15.8 (6) 21.1 (8) 0.768
Cube Worse 23.7 (9) 28.9 (11) 0.795
Ring Worse 15.8 (6) 2.6 (1) 0.108
Coin Worse 10.5 (4) 7.9 (3) 1.000
Behaviour Worse 26.3 (10) 28.9 (11) 1.000
Tone Decreased 34.2 (13) 56.8 (21^) 0.084
*comparison of 2 × 2 for AS7 vs MAS7
^Tone 1 less than N for MAS7 on each comparisonMalaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
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tion and a functional level of tone. Indeed these results are
in keeping with the few detailed psychomotor studies in
adults [13-17] where mefloquine (and artesunate) do not
appear to be detrimental to coordination and behavior.
The tone and behaviour tasks were based on manipula-
tion and observation of the child and were therefore con-
sistently completed. However there were difficulties with
interpreting tone and behaviour scores since the scores for
both were significantly influenced by the presence of fever
and vomiting. As well tone was negatively correlated with
behavior. There was a significant improvement in behav-
iour by day 7 and a further gain by day 28. Similarly, there
was a significant reduction in tone with treatment by day
7 and further still by day 28. Most of the improvement
was present at day 7 presumably due to the resolution of
fever and vomiting and clearance of malaria parasites.
Assessing the neurological status of young children who
are acutely unwell with malaria is extremely difficult
[38,39]. Plasmodium falciparum infection is likely to nega-
tively influence CNS function [40-43], reflected in the
observation that some elements of the assessment were
completed by only 30% of children on day 0. Those who
were the most unwell were unable to cooperate with the
tests, and conversely, those who were able to cooperate
Table 5: Paired comparison of the time (median [min-max] seconds) to put coins into the coin box at each specified day
Days of comparison Time N pairs Controls (well, no fever)
Earlier day Later day P*
0-7 6 coins 18 13.8 [11-32] 13.8 [11-27.5] 0.722
12 coins 18 31.5 [23-94] 30 [23.5-55.5] 0.554
0-28 6 coins 15 14 [11-32] 14 [9-18] 0.172
12 coins 14 32 [25-94] 29 [22-50] 0.158
7-9 6 coins n.a n.a n.a n.a
12 coins n.a n.a n.a n.a
7-10 6 coins n.a n.a n.a n.a
12 coins n.a n.a n.a n.a
7-14 6 coins 19 15.0 [10-48] 14.8 [11-39.5] 0.157
12 coins 17 30.5 [23.5-55.5] 31.5 [23.5-69.0] 0.820
7-28 6 coins 17 14.5 [10.5-35.5] 13.5 [8.5-23.5] 0.055
12 coins 16 29.5 [23.5-76] 29 [22-83] 0.510
Malaria - AS7
0-7 6 coins 12 12.3 [10-26.5] 13.5 [10-35.5] 0.166
12 coins 12 27.5 [22-68.5] 26.5 [22-58.5] 0.413
0-28 6 coins 10 13 [10-27] 13 [9-23] 0.673
12 coins 9 28 [22-69] 28 [20-73] 0.260
7-9 6 coins 15 14.5 [10-35.5] 13.5 [7.5-31] 0.459
12 coins 14 27.0 [21.0-58.5] 27.5 [20-69] 0.126
7-10 6 coins 16 15.3 [10-35.5] 16.8 [8.5-30.5] 0.529
12 coins 14 32.0 [21.0-58.5] 33.5 [20-52.5] 0.700
7-14 6 coins 14 14.3 [10.5-35.5] 17.3 [8.0-28.5] 0.201
12 coins 12 25.8 [21.0-58.5] 29.0 [19-78.0] 0.480
7-28 6 coins 13 14 [10.5-35.5] 14 [8.5-22.5] 0.059
12 coins 11 25.0 [21.0-56.0] 28.0 [20-55.0] 0.722
Malaria - MAS7
0-7 6 coins 18 15 [10-23] 14.5 [7-30.5] 0.604
12 coins 18 32.3 [21-47.5] 29.8 [20-51] 0.066
0-28 6 coins 16 15 [10-23] 14 [6-26] 0.277
12 coins 14 33 [21-48] 30 [20-62] 0.220
7-9 6 coins 20 15.8 [7-34.5] 13.8 [8-31] 0.067
12 coins 19 33 [20-65.5] 30 [18-50] 0.040
7-10 6 coins 20 15.5 [7-34.5] 13.3 [8.5-26] 0.030
12 coins 18 30.5 [20-52.5] 30.8 [18-67.5] 0.924
7-14 6 coins 19 15.5 [7-34.5] 14.5 [8.5-33.0] 0.573
12 coins 17 31.0 [22.5-52.5] 31.0 [20.0-70] 0.135
7-28 6 coins 20 15.5 [7-34.5] 14.3 [6-28.5] 0.025
12 coins 18 30.5 [20.-61.5] 30.0 [20-61.5] 0.316
*P = Wilcoxon Signed Ranks Test for paired samples at specified days; N = number of pairs analysedMalaria Journal 2009, 8:207 http://www.malariajournal.com/content/8/1/207
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were the least unwell and in this study were able to score
as well as controls. It could be argued that the ability to
participate in the test represents an equally useful evalua-
tion of neurological status in children with malaria as
does the actual score achieved when testing is possible. P.
falciparum infection is associated with fever and the chil-
dren with fever were less likely to have a valid test score in
this study. Yet P. falciparum per se affects neurological
function [40-43], and this is reflected in the observations
that in young, unwell children paediatricians typically
examine for fever and hypotonia [44] but the tone scores
in P. falciparum affected children were highest on admis-
sion: with fever being associated with higher tone scores
which became lower following treatment. Treating falci-
parum malaria with either regime significantly improved
the rates of valid test scores, representing an improvement
in neurological function that may overwhelm any possi-
ble subtle neurological side-effect of artesunate or meflo-
quine.
It must be conceded that the ideal test conditions did not
apply in this setting. Preferably one would know the base-
line abilities per item of children tested without the pres-
ence of illness. To establish the baseline level children
would need repeated testing at different ages to account
for normal developmental growth. Alternatively, by stud-
ying a larger number of children, age norms could be
established or by inclusion of febrile P. vivax and febrile
non-malaria children, P. falciparum effects could be differ-
entiated from fever effects. Sophisticated field equipment,
such as audiometry testing is another method that might
be used but even this can be affected by malaria fever [28].
However, under difficult circumstances these tests have
provided preliminary information on the safety of these
drugs in young children. The neurological tests proved
sufficiently sensitive to detect changes in performance in
these children over time and paired data analysis allowed
a powerful statistical test to determine recovery. A greater
sample size may have allowed more subtle differences to
be detected. A subtle effect of mefloquine may be more
readily detected in future studies of mefloquine where
"well" infants receive the drug as intermittent preventive
treatment. Another limitation of the study was the length
of follow up and a further examination at day 42 or day
63 would have been useful to confirm if the rising trend
for increased valid test scores conformed with the control
children.
In the past 15 years, 8,172 children under five years have
been treated for falciparum malaria most of whom
received the combination of artesunate and mefloquine
and approximately 564 have been followed up weekly (6-
9 weeks) for side effects in chemotherapy studies at
Shoklo Malaria Research Unit. Very few CNS related
adverse events have been observed with this regimen
when the ground rules are adhered to. They include with-
holding mefloquine when the malaria is cerebral or
severe; when the patient is epileptic; when there is a his-
tory of psychiatric problems, convulsions or previous
problems on mefloquine; when mefloquine has been
used for treatment in the past two months; or when the
patient weighs less than 5 kg. As shown in this small
study, mefloquine clearly reduces the risk of developing P.
vivax  during follow-up and the mefloquine-artesunate
combination was not associated with worse performance
on neurological testing. Given these findings, and the
potential long-term complications of poorly-treated
malaria infection in children [39,45], mefloquine-artesu-
nate combination therapy should continue to be admin-
istered to children with acute uncomplicated falciparum
malaria.
Conclusion
Assessment of neurologic function in acutely unwell chil-
dren with P. falciparum is difficult and affected by fever
and vomiting. Treatment results in a significant improve-
ment in the ability of children to participate in neurolog-
ical testing and no worsening of performance on those
tests. Neither artesunate nor mefloquine resulted in signif-
icant impairment of behavior or motor function in very
young Karen children when compared with non-febrile
controls.
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